Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.08T
Market cap1.08T
Price-Earnings ratio
42.09
Price-Earnings ratio42.09
Dividend yield
0.55%
Dividend yield0.55%
Average volume
2.51M
Average volume2.51M
High today
$1,147.54
High today$1,147.54
Low today
$1,137.96
Low today$1,137.96
Open price
$1,179.79
Open price$1,179.79
Volume
15.43K
Volume15.43K
52 Week high
$1,249.45
52 Week high$1,249.45
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

As of today, Eli Lilly(LLY) shares are valued at $1,138.46. The company's market cap stands at 1.08T, with a P/E ratio of 42.09 and a dividend yield of 0.55%.

During the trading session on 2026-07-21, Eli Lilly(LLY) shares reached a daily high of $1,147.54 and a low of $1,137.96. At a current price of $1,138.46, the stock is +0.0% higher than the low and still -0.8% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 15.43K, versus its average volume of 2.51M.

The stock's 52-week range extends from a low of $623.78 to a high of $1,249.45.

The stock's 52-week range extends from a low of $623.78 to a high of $1,249.45.

LLY News

MarketWatch 45m
Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications - MarketWatch

...

Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications - MarketWatch
The Wall Street Journal 57m
Weight-Loss Wars Latest: Novo Nordisk Sues Eli Lilly

Ozempic maker Novo Nordisk has filed a lawsuit against Eli Lilly, arguing it uses deceptive advertising to mislead consumers. The complaint accuses Eli Lilly o...

Weight-Loss Wars Latest: Novo Nordisk Sues Eli Lilly
The Wall Street Journal 1h
Novo Nordisk Files Deceptive Advertising Lawsuit Against Rival Eli Lilly

Novo Nordisk says it sent its rival a cease-and-desist letter in April. Mads Claus Rasmussen / AFP / Getty Images Novo Nordisk NOVO.B -1.68 %decrease; down poi...

Novo Nordisk Files Deceptive Advertising Lawsuit Against Rival Eli Lilly

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
12.9%
Sell
6.5%

More LLY News

TipRanks 1h
Novo Nordisk files lawsuit against ‘misleading’ GLP-1 ads from Eli Lilly

Novo Nordisk (NVO) announced that it has filed a lawsuit against Eli Lilly (LLY) in the United States District Court for the District of New Jersey for what it...

TipRanks 1h
Novo Nordisk suing Eli Lilly over weight-loss ads, Bloomberg reports

Novo Nordisk (NVO) said in U.S. federal court that it is suing Eli Lilly (LLY), claiming that its competitor’s advertising for its obesity shot Zepbound and dia...

CNBC 1h
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising

Key Points Novo Nordisk filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its blockbuster obesity and diabetes drugs are designed t...

Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Simply Wall St 13h
The Bull Case For Eli Lilly Could Change Following Its Deeper Role In Illumina’s Billion Cell Atlas

In January 2026, Illumina announced the launch of its Billion Cell Atlas alliance, naming Eli Lilly as a founding member in a program that uses CRISPR-based, la...

The Bull Case For Eli Lilly Could Change Following Its Deeper Role In Illumina’s Billion Cell Atlas
Nasdaq 19h
Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?

Key Points Lilly stock has soared in the double-digits over the past couple of months. A potential stock split could bring the stock price down to more access...

Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?
Nasdaq 2d
Cathie Wood Is Loading Up on This GLP-1 Stock That Has Soared 1,600% Over the Past 10 Years

Key Points Ark Investment Management recently bought more shares of Eli Lilly. The pharmaceutical leader has a strong grip on the fast-growing GLP-1 market....

Cathie Wood Is Loading Up on This GLP-1 Stock That Has Soared 1,600% Over the Past 10 Years
Nasdaq 3d
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1

Key Points Viking Therapeutics just launched its next-gen weight loss program. Novo Nordisk and Eli Lilly are already deep into the development process with c...

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.